Sayanh Somrithipol

Title: Sayanh Somrithipol: Innovator in Antituberculosis Compounds

Introduction

Sayanh Somrithipol is a notable inventor based in Pathumthani, Thailand. He has made significant contributions to the field of biotechnology, particularly in the development of antituberculosis compounds. His work focuses on the isolation and application of novel alkaloids that show promise in treating tuberculosis.

Latest Patents

Somrithipol holds a patent for his discovery of three new alkaloids, known as Hirsutellones A, B, and C. These compounds are produced in cultures of specific fungus strains, including BCC 2594 and BCC 7579. The Hirsutellones have demonstrated potent growth inhibitory activity against the H37Ra strain of tuberculosis, with a minimum inhibitory concentration (MIC) value of 0.78 µg/ml. Importantly, these compounds exhibit weak or no cytotoxicity to mammalian cells, indicating their potential as safe therapeutic agents. The patent also describes methods for isolating the Hirsutellones, which could facilitate further research and development.

Career Highlights

Somrithipol is affiliated with the National Center for Genetic Engineering & Biotechnology, which is part of the National Science & Technology Development Agency. His role at this esteemed institution allows him to engage in cutting-edge research and contribute to advancements in biotechnology.

Collaborations

Some of his notable coworkers include Masahiko Isaka and Nigel Leslie Hywel-Jones. Their collaboration likely enhances the research environment and fosters innovation in their respective fields.

Conclusion

Sayanh Somrithipol's work in developing antituberculosis compounds represents a significant advancement in the fight against this disease. His innovative approach and dedication to research contribute to the ongoing efforts to improve public health.